Skip to content

New clinical stategy for hepatocellular carcinoma therapy combined with adjuvant adenovirus-thymidine kinase gene

New clinical stategy for hepatocellular carcinoma therapy combined with adjuvant adenovirus-thymidine kinase gene

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-12002985
Enrollment
Unknown
Registered
2012-12-24
Start date
2008-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hepatocellular carcinoma

Interventions

Liver transplantation:Liver transplantation combined with ADV-TK gene
The hepatic resection:The hepatic resection combined with ADV-TK gene
TACE+radio frequency:TACE+radio frequency combined with ADV-TK gene

Sponsors

Beijing YouAn Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Liver transplantation: 1) Primary liver cancer beyond Milan criteria, accompanied by hepatic lymph node metastasis; 2) Accompanied by portal vein tumor thrombus, not more than the main portal vein 1/2; 3) Primary liver cancer confirmed by histopathology; 4) Aged 18-70 years old; 5) Signed the informed consent. 2. The hepatic resection: 1) Primary liver cancer; 2) Liver lesions localized to one lobe of liver or half liver can operation resection; 3) Resection range from operation margin <=3cm; 4) Signed the informed consent. 3. TACE+radio frequency: 1) Primary liver cancer; 2) Liver lesions localized to one lobe of liver or half liver; 3) Liver lesions edge from important vascular and biliary <=3cm; 4) Liver lesions can be resected but the patient does not agree with the operation; 5) Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to ADV-TK and Ganciclovir or others; 2. After transplantation, the vital signs of the patients' recovery instability; 3. Poor compliance.

Design outcomes

Primary

MeasureTime frame
DFS;survival;Control rate;

Contacts

Public ContactNing Li
liningya@ccmu.edu.cn+86 010-83997001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026